09/13/21 8:00 AMNasdaq : ANEBclinical trialAnebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical TrialAnebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced the completion of finished product manufacturing of its lead drug ANEB-001 for use in the Company’ s upcoming Phase 2 clinical study.RHEA-AIneutral
09/07/21 8:00 AMNasdaq : ANEBconferencesAnebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceAnebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced that management will be participating in the H.C. Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel...RHEA-AIneutral
08/12/21 8:00 AMNasdaq : ANEBmanagementAnebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two MembersAnebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced the formation of a Scientific Advisory Board (SAB) toRHEA-AIneutral
06/21/21 4:05 PMNasdaq : ANEBearningsAnebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial ResultsAnebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid intoxication and substance addiction, today reported recent business highlights and announced financial results for theRHEA-AIneutral
05/06/21 8:00 PMNasdaq : ANEBIPOofferingAnebulo Pharmaceuticals Announces Pricing of Initial Public OfferingAnebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction, today announced the pricing of its initial public offering of 3,000,000 shares ofRHEA-AIneutral
